{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016277","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.779026+00:00","generated_at":"2026-06-15T05:04:14.853166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Abeona Therapeutics Q1 net loss $9.1M; cash runway into Q3 2024; advancing EB-101 BLA submission","bullets":["Net loss of $9.1M ($0.54 loss per share) vs $22.0M ($3.80) in Q1 2022; license revenue nil.","Cash, equivalents, short-term investments $40.7M at Mar 31, 2023, down from $52.5M at Dec 31, 2022; cash runway into Q3 2024.","Progress toward BLA submission for EB-101 in RDEB in late Q2/early Q3 2023; pre-BLA meeting request submitted to FDA.","Additional Phase 3 VIITAL data presented at ISID; preclinical AAV ophthalmology data (ABO-504, ABO-503, ABO-505) at ASGCT May 16-20.","R&D expenses $8.0M, G&A $4.0M for Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016277","json":"https://secwatch.observer/filing/0001493152-23-016277.json","markdown":"https://secwatch.observer/filing/0001493152-23-016277.md","text":"https://secwatch.observer/filing/0001493152-23-016277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/0001493152-23-016277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:04:14.853166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d3eaa9fbdb4cb3d6d4fde7526c36bb3b5891308","claim":"ABEONA THERAPEUTICS INC. reported the first quarter of 2023 results: revenue nil, net income Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share, EPS $0.54 loss per common share. Guidance reaffirmed.","evidence_excerpt":"Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/0001493152-23-016277-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"nil"},{"label":"Net income","value":"Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share"},{"label":"EPS","value":"$0.54 loss per common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}